Since the receptor complexes for IFN-I and IFN-γ both signal via the JAK-STAT pathway, simultaneous inhibition of these pathways may help explain the therapeutic effects of JAK inhibitors, which are increasingly used for the treatment of HLH and MAS (37). Here, SOAT1 is linked to macrophage activation syndrome.